Boehringer Ingelheim
For Healthcare Professionals
Image-1

Metabolic

About 425 million adult people in the world are living with diabetes, with Type 2 diabetes accounting for 90 percent of all cases1. This number is projected to increase to 629 million people by 20451. Type 2 diabetes is a chronic, progressive condition and long-term complications include stroke, heart attack and cardiovascular death as well as diabetic kidney disease, retinopathy, arm and leg amputations and autonomic neuropathy. In addition to the now marketed products from our own R&D, we are also focused on cardiometabolic indications with a high unmet medical need.

1 Diabetes Atlas 8th edition 2017, International Diabetes Federation. http://www.diabetesatlas.org (link is external) (accessed April 2018).

Learn more
Image-1

Linagliptin (Trajenta®)

Treatment of adults with type 2 diabetes mellitus to improve glycaemic control in conjunction with diet and exercise, as monotherapy or as add on to metformin, sulphonylureas, thiazolidinediones, insulin (with or without metformin and/or pioglitazone and/or sulphonylureas or metformin plus SGLT2 inhibitors.
Learn more
Learn more
Image-1

Linagliptin Metformin HCl (Trajenta Duo®)

Linagliptin + Metformin HCl (Trajenta Duo®) is indicated as adjunct to exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin HCl is appropriate.
Learn more

Cardiovascular

Cardiovascular disease, including heart disease and stroke, is a major global health concern and the leading cause of death and disability worldwide1. At Boehringer Ingelheim we address unmet medical need by providing innovative treatments that improve the care of patients suffering from a range of cardiovascular conditions including irregular heartbeat (atrial fibrillation), stroke, blood clots in deep veins or lungs (deep vein thrombosis or pulmonary embolism), high blood pressure (hypertension) or heart attack (myocardial infarction).

1 Vilahur G et al. Eur Heart J Suppl 2014; 16(Suppl_A): A7-A11.

Learn more
Image-1

Telmisartan (Micardis®)

Telmisartan (Micardis®) is used in the treatment of essential hypertension. Prevention of cardiovascular morbidity and mortality in patients ≥55 years at high risk of cardiovascular disease. As fixed dose combination Telmisartan + Hydrochlorothiazide (HCTZ) is indicated in patients whose blood pressure is not adequately controlled on telmisartan or HCTZ alone. Available formats: 40mg and 80mg
Learn more

Inflammation